OBJECTIVE: To review the efficacy and safety of liraglutide 3.0 mg for weight loss. DATA
SOURCE: A literature search was performed using PubMed and MEDLINE from 2000 to …

Objective To review the efficacy, safety, and clinical applicability of liraglutide for weight
management from phase III clinical trials. Methods A search of the English language …

Obesity continues to pose a major public health risk to the United States and across the
world, with an estimated one‐third of adult Americans being defined as obese. Obesity …

Background Obesity is a chronic disease with serious health consequences, but weight loss
is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like …

Background As the pandemic of obesity presents an increasing serious health challenge
worldwide, additional medical interventions, especially pharmacotherapy, should be …

Introduction: Obesity is a global health challenge, and pharmacologic options are emerging.
Once daily subcutaneous administration of 3 mg liraglutide, a glucagon like peptide-1 …

Introduction: Obesity is a global epidemic with important healthcare and financial
implications. Most current antiobesity pharmacological therapies are unsatisfactory due to …

Introduction: The prevalence of obesity is increasing worldwide and associated conditions,
particularly type 2 diabetes mellitus (T2DM), also show increasing prevalence. Lifestyle …

Objective: Liraglutide is a glucagon-like peptide 1 receptor agonist which acts through
peripheral and central receptor pathways affecting food intake. Preliminary identification of …

Background: Several drugs have been currently approved for the treatment of obesity. The
pharmacokinetic of liraglutide, as well as the treatment of type 2 diabetes mellitus, have …